Synthesis and Evaluation of Zwitterionic Carbohydrate Immunostimulants

两性离子碳水化合物免疫增强剂的合成与评价

基本信息

  • 批准号:
    9109179
  • 负责人:
  • 金额:
    $ 18.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-01-15 至 2017-12-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Although the use of vaccines to combat infectious diseases has greatly improved human health, they are poorly immunogenic and requires multiple doses for protection. As such, vaccines are co-administered with an adjuvant to enhance immunity. Numerous classes of vaccine adjuvants have been developed and showed the desired immune response over the past several decades. Unfortunately, only a few adjuvants are considered to be sufficiently potent and clinically liable for use in humans. Alum, a mixture of aluminum hydroxide and phosphate salts, remains the dominant adjuvant with extensive safety record approved for use in human vaccination. In efforts to discover new adjuvants, an unusual class of carbohydrates, zwitterionic polysaccharides (ZPSs), containing both negative and positive charge motifs in their repeating units, were found to activate CD4+ T-cell-dependent immune responses and modulate host cytokine responses to bacterial infection. ZPSs when co-administered with antigen tetanus toxoid increase the specific antibody tier, illustrating their capacity to serve as potential vaccine adjuvants in vivo. One of the best characterized ZPSs is zwitterionic polysaccharide PS A1, isolated from capsular Bacteroides fragilis. Studies showed that glycoconjugates, generated from conjugation of PS A1 to tumor-associated mucin antigen TN, elicits high titer antibodies that are specific and selective for the TN hapten. Despite the promise of PS A1 as a potential adjuvant, obtaining it from natural sources is a complicated process of extraction and purification that results in the production of minute, relatively impure quantities and could alter its structure. Since FDA has strict regulation regarding the purity and quality of vaccine adjuvants for use in humans, a synthetic source must be developed for PS A1 to be utilized as a clinically relevant adjuvant. The main goal of this proposal will address these challenges through the chemical synthesis of natural and non-natural PS A1 oligosaccharides with defined repeating units utilizing our recently developed nickel-catalyzed α-glycosylation methodologies. This proposed effort will deliver defined PS A1 molecules in high purity without batch-to-batch variation and provide tools for studying their roles as adjuvants and exploring structure-relationship activity (SAR) studies. 1
 描述(申请人提供):虽然使用疫苗来对抗传染病极大地改善了人类健康,但它们的免疫原性很差,需要多次接种才能保护。因此,疫苗与佐剂联合接种以增强免疫力。在过去的几十年里,许多种类的疫苗佐剂已经被开发出来,并显示出理想的免疫反应。不幸的是,只有少数佐剂被认为是足够有效的,临床上可以用于人类。明矾,一种 氢氧化铝和磷酸盐的混合物,仍然是主要的佐剂,有广泛的安全记录,被批准用于人类疫苗接种。在寻找新的佐剂的过程中,发现了一类不寻常的碳水化合物--两性离子多糖(ZPS),它的重复单元中既含有正负电荷基序,又能激活CD4+T细胞依赖的免疫反应,并调节宿主细胞因子对细菌感染的反应。当ZPS与破伤风类毒素抗原联合注射时,可以增加特异性抗体水平,说明它们在体内作为潜在的疫苗佐剂的能力。最具特性的ZPS之一是从脆弱类杆菌胶囊中分离得到的两性离子多糖PS A1。研究表明,PS A1与肿瘤相关粘蛋白抗原TN偶联产生的糖偶联物可诱导针对TN半抗原的高滴度抗体。尽管PS A1有望成为一种潜在的佐剂,但从天然来源获得PS A1是一个复杂的提取和纯化过程,导致产生微小的、相对不纯的数量,并可能改变其结构。由于FDA对人类使用的疫苗佐剂的纯度和质量有严格的规定,因此必须开发一种合成来源,才能将PS A1用作临床相关佐剂。这项提案的主要目标是利用我们最近开发的镍催化α糖基化方法,通过化学合成具有特定重复单元的天然和非天然PS A1寡糖来应对这些挑战。这项拟议的工作将提供定义的PS A1分子的高纯度,没有批次到批次的变化,并为研究它们作为佐剂的作用和探索结构关系活性(SAR)研究提供工具。1

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hien M Nguyen其他文献

Hien M Nguyen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hien M Nguyen', 18)}}的其他基金

Development of Catalytic Glycosylations and Biologically Important Glycosaminoglycans
催化糖基化和具有生物学重要性的糖胺聚糖的发展
  • 批准号:
    10622180
  • 财政年份:
    2023
  • 资助金额:
    $ 18.66万
  • 项目类别:
Synthesis and Evaluation of Carbohydrate Vaccine Adjuvants
碳水化合物疫苗佐剂的合成与评价
  • 批准号:
    10538831
  • 财政年份:
    2022
  • 资助金额:
    $ 18.66万
  • 项目类别:
Synthesis and Evaluation of Carbohydrate Vaccine Adjuvants
碳水化合物疫苗佐剂的合成与评价
  • 批准号:
    10642889
  • 财政年份:
    2022
  • 资助金额:
    $ 18.66万
  • 项目类别:
Strategies for Expedited Synthesis of Sulfated Aminoglycans
硫酸化氨基聚糖的快速合成策略
  • 批准号:
    10371884
  • 财政年份:
    2020
  • 资助金额:
    $ 18.66万
  • 项目类别:
Strategies for Expedited Synthesis of Sulfated Aminoglycans
硫酸化氨基聚糖的快速合成策略
  • 批准号:
    10594458
  • 财政年份:
    2020
  • 资助金额:
    $ 18.66万
  • 项目类别:
Catalytic Methods for Stereoselective 1,2-Cis Glycosylation
立体选择性 1,2-顺式糖基化的催化方法
  • 批准号:
    9163857
  • 财政年份:
    2016
  • 资助金额:
    $ 18.66万
  • 项目类别:
Synthesis of Complex Carbohydrates.
复杂碳水化合物的合成。
  • 批准号:
    8640956
  • 财政年份:
    2012
  • 资助金额:
    $ 18.66万
  • 项目类别:
Synthesis of Complex Carbohydrates.
复杂碳水化合物的合成。
  • 批准号:
    8826141
  • 财政年份:
    2012
  • 资助金额:
    $ 18.66万
  • 项目类别:
Tailoring Structures of Sulfated Oligosaccharides for Modulating Heparanase Activity
用于调节乙酰肝素酶活性的硫酸低聚糖的剪裁结构
  • 批准号:
    10164799
  • 财政年份:
    2012
  • 资助金额:
    $ 18.66万
  • 项目类别:
Tailoring Structures of Sulfated Oligosaccharides for Modulating Heparanase Activity
用于调节乙酰肝素酶活性的硫酸低聚糖的剪裁结构
  • 批准号:
    9816301
  • 财政年份:
    2012
  • 资助金额:
    $ 18.66万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 18.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 18.66万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 18.66万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 18.66万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 18.66万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 18.66万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 18.66万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 18.66万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 18.66万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 18.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了